CN110603254B - 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法 - Google Patents

被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法 Download PDF

Info

Publication number
CN110603254B
CN110603254B CN201780084999.4A CN201780084999A CN110603254B CN 110603254 B CN110603254 B CN 110603254B CN 201780084999 A CN201780084999 A CN 201780084999A CN 110603254 B CN110603254 B CN 110603254B
Authority
CN
China
Prior art keywords
methyl
pyrazole
thiazol
carboxylic acid
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084999.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110603254A (zh
Inventor
A.M.西迪奎
S.西布拉特
M.德里
L.康斯坦帝诺-福格特
C.格兰德-梅特
N.布鲁诺-拉图尔
G.W.希普斯
A.B.库珀
V.奥扎
M.W.科斯图拉
M.卢瑟
J.莱文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Priority to CN202410345199.5A priority Critical patent/CN118930533A/zh
Publication of CN110603254A publication Critical patent/CN110603254A/zh
Application granted granted Critical
Publication of CN110603254B publication Critical patent/CN110603254B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780084999.4A 2016-11-30 2017-11-29 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法 Active CN110603254B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410345199.5A CN118930533A (zh) 2016-11-30 2017-11-29 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428271P 2016-11-30 2016-11-30
US62/428,271 2016-11-30
PCT/US2017/063774 WO2018102453A1 (en) 2016-11-30 2017-11-29 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410345199.5A Division CN118930533A (zh) 2016-11-30 2017-11-29 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法

Publications (2)

Publication Number Publication Date
CN110603254A CN110603254A (zh) 2019-12-20
CN110603254B true CN110603254B (zh) 2024-04-12

Family

ID=62241871

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780084999.4A Active CN110603254B (zh) 2016-11-30 2017-11-29 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN202410345199.5A Pending CN118930533A (zh) 2016-11-30 2017-11-29 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410345199.5A Pending CN118930533A (zh) 2016-11-30 2017-11-29 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法

Country Status (10)

Country Link
US (2) US11325903B2 (https=)
EP (1) EP3548482A4 (https=)
JP (1) JP7373992B2 (https=)
CN (2) CN110603254B (https=)
AU (1) AU2017366901B2 (https=)
BR (1) BR112019011044A2 (https=)
CA (1) CA3081983A1 (https=)
IL (1) IL266930B2 (https=)
MX (1) MX2019006299A (https=)
WO (1) WO2018102453A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
US12150934B2 (en) * 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
BR112020024794A2 (pt) * 2018-06-07 2021-03-02 Bantam Pharmaceutical, Llc métodos de tratamento de câncer com compostos de pirrol e pirazol substituídos e diagnóstico de câncer suscetível a tratamento com compostos de pirrol e pirazol substituídos
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
JP2022534429A (ja) * 2019-05-31 2022-07-29 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニー １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形
CN114867724B (zh) * 2019-05-31 2025-11-07 班塔姆制药有限责任公司 用于制备噻唑基吡唑甲酸及其中间体的方法
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
JP7808058B2 (ja) * 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024543976A (ja) * 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN116678810A (zh) * 2022-02-23 2023-09-01 武汉市鼎华双雄生物科技有限责任公司 细胞增殖免疫荧光检测试剂盒及其应用
CN117003651B (zh) * 2023-09-28 2024-01-02 广东嘉博制药有限公司 一种l-肾上腺素的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795184A (zh) * 2003-04-03 2006-06-28 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体－5调节剂
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
US20150274717A1 (en) * 2012-10-22 2015-10-01 Egenix, Inc. Compositions And Methods For Treating Or Preventing Diseases Or Disorders Associated With Misregulated EIF4E
CN108349962A (zh) * 2015-06-01 2018-07-31 班塔姆制药有限责任公司 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
EP1104759B1 (en) 1999-12-03 2003-10-22 Pfizer Products Inc. Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents
AU2003226252A1 (en) 2002-04-04 2003-10-20 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
CN101835377B (zh) 2007-08-27 2014-12-10 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
CN108040481B (zh) 2015-04-24 2020-10-30 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
US12150934B2 (en) * 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
JP2022534429A (ja) * 2019-05-31 2022-07-29 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニー １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795184A (zh) * 2003-04-03 2006-06-28 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体－5调节剂
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
US20150274717A1 (en) * 2012-10-22 2015-10-01 Egenix, Inc. Compositions And Methods For Treating Or Preventing Diseases Or Disorders Associated With Misregulated EIF4E
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
CN108349962A (zh) * 2015-06-01 2018-07-31 班塔姆制药有限责任公司 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4- (4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3;Li-Min Duan等;《Bioorganic & Medicinal Chemistry》;20150807;第23卷(第18期);第6112页 *
Synthesis and Screening of Fluoro Substituted Pyrazolyl Benzoxazoles;R. K. JADHAV等;《ORIENTAL JOURNAL OF CHEMISTRY》;20151231;第31卷(第2期);第969-970页 *

Also Published As

Publication number Publication date
CA3081983A1 (en) 2018-06-07
MX2019006299A (es) 2019-11-12
JP7373992B2 (ja) 2023-11-06
AU2017366901A1 (en) 2019-07-11
AU2017366901B2 (en) 2022-09-29
RU2019120233A (ru) 2021-01-11
US20230076820A1 (en) 2023-03-09
CN118930533A (zh) 2024-11-12
IL266930B1 (en) 2025-05-01
CN110603254A (zh) 2019-12-20
US20190345152A1 (en) 2019-11-14
EP3548482A1 (en) 2019-10-09
EP3548482A4 (en) 2020-08-19
US11325903B2 (en) 2022-05-10
NZ754827A (en) 2025-10-31
WO2018102453A1 (en) 2018-06-07
RU2019120233A3 (https=) 2021-03-11
IL266930B2 (en) 2025-09-01
BR112019011044A2 (pt) 2019-10-08
IL266930A (en) 2019-07-31
JP2019536785A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
CN110603254B (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
US12150934B2 (en) Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
US9255089B2 (en) Benzimidazolone derivatives as bromodomain inhibitors
KR102680164B1 (ko) Rock 억제제로서의 페닐아세트아미드
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
AU2014228175A1 (en) Tricyclic heterocycles as BET protein inhibitors
WO2023224998A1 (en) Inhibitors of parg
EP4526304A1 (en) Inhibitors of parg
WO2024145505A1 (en) Pyrimidine carboxamide compounds
JP2019001715A (ja) 三環性化合物
KR20230022861A (ko) Tead 결합제로서 유용한 트리시클릭 헤테로사이클
RU2787994C2 (ru) Замещенные соединения пиразола и способы их применения для лечения гиперпролиферативных заболеваний
WO2025223550A1 (zh) 吡啶或吡嗪并三环化合物及其药用组合物和应用
HK1220692B (en) Benzimidazolone derivatives as bromodomain inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant